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Abstract
This nation-wide survey on the epidemiology of vancomycin-resistant enterococci (VRE) included 142 healthcare
institutions and showed an increasing number of VRE colonizations and infections in Switzerland, probably for the
most part due to nosocomial dissemination. The introduction and spread of a new clone, gaps in VRE screening
policies as well as heterogeneity regarding the management of VRE clusters may be possible explanations.
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Introduction
Vancomycin-resistant enterococci (VRE) are multi-drug
resistant organisms (MDROs) that can cause healthcare-
associated infections and increase both length of stay and
in-hospital mortality [1, 2]. The WHO listed VRE as a
pathogen of high priority in its global list of important
antibiotic-resistant bacteria [3]. In Europe, several coun-
tries reported an increasing proportion of vancomycin re-
sistance among invasive isolates of Enterococcus faecium
[4]. In Switzerland, VRE incidence is currently not being
monitored for infection control purposes at a national
level. Moreover, in recent years nosocomial VRE out-
breaks have been reported from several hospitals in
Switzerland [5–7], revealing that VRE is of concern to our
healthcare system. Therefore, an update addressing all
Swiss acute-care hospitals was deemed necessary to evalu-
ate the current VRE epidemiology and identify possible
gaps in the outbreak management strategies.
Methods
This survey included 205 public or private institutions
providing inpatient care in Switzerland. The list of hos-
pitals consisted of acute-care hospitals and was updated
in March 2018 based on the official hospital list of the
Federal Office of Public Health (http://www.bag.ad-
min.ch) with inputs from the Swiss Hospital Society
(http://www.hplus.ch). Psychiatric institutions, palliative
care, long-term care facilities, rehabilitation facilities
and pain therapy centers were excluded. Between May
1st and June 19th 2018, a 37-item questionnaire (Add-
itional file 1) was sent via email to 146 contact individ-
uals responsible for infection control at 205 acute-care
institutions providing inpatient care (all hospitals and
clinics with acute-care beds in Switzerland). Each email
was sent in the respective local language (German,
French or Italian). Two reminders as well as a personal-
ized email were addressed to each non-responding
institution. Overall, 144 institutions answered, corre-
sponding to a 70% response rate. Most of the 61 insti-
tutions that did not complete the survey were small
hospitals (i.e., only three non-responding hospitals had
> 200 beds). After the exclusion of one double entry
and one rehabilitation facility, 142 institutions were in-
cluded in the final analysis (Fig. 1).
The survey was created, pre-tested locally and
shared through the online platform SurveyMonkey®.
We collected epidemiological data of VRE cases.
Moreover, details on VRE outbreaks as well as infor-
mation on VRE outbreak management strategies was
inquired. An outbreak was defined as an unusual or
unexpected increase in VRE colonizations and/or
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infections (i.e., ≥ 2 in the same time period in an in-
dividual hospital). A maximum of two major out-
breaks per institution were analyzed in more detail.
All epidemiological information on both VRE in general
and whether an institution had witnessed VRE outbreaks
was institution-based (n = 142) and not respondent-based
(n = 94) as certain contacts were responsible for multiple
institutions.
Information about VRE outbreak management strategy
was obtained from physicians who were involved in the
management of a VRE outbreak and were therefore
respondent-based (n = 14).
Data were extracted from the online platform to an
Excel® spread-sheet, checked for accuracy and exported
for descriptive analysis using SPSS (Version 25). The in-
cidence rate was expressed in VRE cases per day.
Results
Responding institutions
Overall, 94 respondents answered for 142 institutions,
accounting for 23′803 beds (out of 28′956 operated in
Switzerland in 2018). Seventy-five percent (107) were
small-size (< 200 beds), 18% (26) medium size (200–500
beds), and 6% (9) large-size institutions (> 500 beds).
Ninety-two (65%) hospitals were located in the German-
speaking part of Switzerland. There were 104 (73%) pub-
lic hospitals among the 142 institutions.
VRE epidemiology
From 1st January 2015 to 31st March 2018, VRE cases
were observed in one third of hospitals (46/142, 32%).
Overall, 652 VRE patients were reported, of which 67
(10%) represented invasive infections.
The total number of VRE cases increased from 96 in
the year 2015 to 146 in the first three months of 2018
(Fig. 2a). Of note, the incidence rate increased from 0.26
cases/day in 2015 to 1.58 cases/day in 2018 in the ap-
proximately > 23′000 beds observed (Fig. 2b).
VRE outbreaks in Switzerland
Twenty-three outbreaks were reported during the
study period. Among the 20 major outbreaks ana-
lyzed, 250 VRE cases including 10 bacteremias (4%)
were observed. Eight outbreaks took place on internal
medicine floors, five in a surgical unit and four in an
intensive care unit. Nine, five and two outbreaks
showed a vanB, vanA and mixed pattern of vanA and
vanB resistance types, respectively.
The mean number of outbreaks per year was seven; in
2016 nine outbreaks were observed (Fig. 3). From 1st Janu-
ary 2018 to the beginning of April 2018 five outbreaks were
observed, four of which were ongoing (all of them located
in the German-speaking part of Switzerland) when the data
collection ended. Seventy percent (102/146) of new VRE
cases in 2018 were outbreak-related (i.e., hospital-acquired).
Fig. 1 Survey institutions and respondents. Note: *Most of the 61 institutions that did not complete the survey were small hospitals (i.e., only
three non-respondent hospitals had > 200 beds)
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VRE outbreak management strategies
Frequently used VRE outbreak management strategies
were contact precautions for VRE colonized or infected pa-
tients (14 of 14 respondents, 100%), contact tracing (13/14,
93%) and pre-emptive contact precautions for high-risk
contact patients (12/14, 86%) until negative screening sam-
ples were collected, reinforcement of hand hygiene compli-
ance (14/14, 100%), and implementation of disinfectant
based environmental cleaning (12/14, 86%). Screening
samples of healthcare workers (2/14, 14%) as well
as decolonization of VRE patients (1/14, 7%) were infre-
quently used measures. Heterogeneity was noted regarding
the following measures: temporary ward closure (imple-
mented in 8/14, 57%) or temporary re-organization of
wards into sectors (7/14, 50%), cohorting of contact pa-
tients (5/14, 36%), staff cohorting (7/14, 50%), active
screening cultures irrespective of exposition (performed in
10/14, 71%), and environmental screening cultures (only
performed in 5/14, 36%). Only two hospitals implemented
antimicrobial stewardship measures during an outbreak.
A
B
Fig. 2 Number of VRE cases detected (a) and VRE incidence per day (b) from 2015 to 2018 in 142 Swiss institutions. Note: Fig. B with trend line
(dotted). VRE: vancomycin resistant enterococci. *in 2018 only data for the first quarter were included
Fig. 3 VRE outbreaks in Switzerland per year from 1st January 2015 to early April 2018. Note:* in 2018 only data until the beginning of April
were included
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Emergence of a new clone: The experience of Bern
University hospital
In early 2018, the emergent clone VRE ST796 was de-
tected for the first time and then found to produce mul-
tiple secondary clusters at Bern University Hospital, as
previously reported [8]. This outbreak was ongoing
when the survey was closed. VRE colonization was en-
countered in 68 patients, of whom 56 (86%) were af-
fected by the ST796 clone. Five patients developed an
invasive infection with this clone. Before this outbreak,
ST796 had exclusively been described in Australia and
New Zealand where it exhibited high transmissibility [9].
In the core gene multilocus sequence typing (cgMLST),
all ST796 isolates were found to be virtually indistin-
guishable, underlining the epidemiologic linkage among
these cases [8].
Discussion
This nationwide survey on the VRE epidemiology is repre-
sentative of Switzerland by including 144 institutions and
characterized by an excellent response rate of 70%. The
survey revealed an increasing number of VRE cases de-
tected in 2018, which correlates with an increased number
of outbreaks observed in the German-speaking part of
Switzerland during the first three months of 2018.
This trend is in line with the rise of VRE prevalence and
VRE outbreaks reported in some of the surrounding Euro-
pean countries, notably Italy and Germany, as reported by
the European Center for Disease Prevention and Control
[10, 11]. Interestingly, the European map is very heteroge-
neous concerning the prevalence of VRE and follows no
distinct geographical pattern compared to many other
multi-resistant bacteria. For example, France and Austria
experienced a comparatively lower level of reported inva-
sive isolates. To date, the reasons for the different VRE
distribution in Europe remain unknown.
Recently, the efficient dissemination of a new clone
(ST796) was described in two hospitals that participated
in this survey [8]. The clinical significance of this strain
compared to other VRE strains remains to be deter-
mined. A high rate of bloodstream infections with VRE
ST796 amongst all sequence typed E. faecium bacter-
emias was observed in Australia, where ST796 was first
described [9, 12]. However, the VRE prevalence is higher
in Australia than in Switzerland and the rate of invasive
infections probably reflect the high colonization preva-
lence in the patient population. Certainly, this clone has
been characterized by a rapid intra- and inter-hospital
spread with a propensity to adapt, probably in response to
specific hospital environments [9, 13]. Moreover, a recent
Swiss survey of screening practices for detecting carriers of
MDROs illustrated a lack of awareness of the potential
spread of VRE by means of unidentified carriers (manu-
script in preparation, personal communication, S. Harbarth,
Geneva). The marked upward trend in incidence is of par-
ticular concern, as several outbreaks were still ongoing in
early April 2018. Moreover, a heterogeneity regarding the
management of VRE outbreaks appears to characterize
current infection prevention and control practices in
Switzerland.
This study has several limitations. First, mean inci-
dence rates were calculated using days as a denominator,
leading to possible overestimation of the total incidence
(e.g., seasonal increase of VRE cases during a specific
year of observation). Second, an external validation of
the respondents’ answers was not performed. Third,
bacteremia and invasive infection rates should be inter-
preted with caution as these data were not available in all
included institutions. Fourth, we excluded long-term care
facilities and rehabilitation centers, which may represent
an underestimated reservoir of multi-drug resistant organ-
isms [14]. Fifth, our outbreak definition included both
small clusters and large outbreaks; however, only 30% of
the observed outbreaks included < 5 VRE detections. Fi-
nally, we cannot rule out the possibility that a patient with
VRE carriage was recorded by more than one institution
due to multiple presentations, leading to a possible over-
estimation of the total burden of VRE.
In conclusion, these findings highlight the emergence of
VRE in parts of Switzerland not affected before, probably
for the most part in the nosocomial setting. A harmonized
nationwide strategy for VRE containment that includes ac-
tive screening surveillance, uniform standards of detection
and outbreak management, reporting at a national level
with a central surveillance as well as guidance for patient
transfers should therefore be implemented.
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